Increased lesional IL-36γ levels have also been described (Johnston et al., 2017) and a blocking anti-IL36R antibody has been recently approved for the treatment of generalized pustular psoriasis (Bachelez et al., 2021; Elewski et al., 2023). The gene discussed is IL1RL2; the disease is generalized pustular psoriasis.